I
Immunocore Holdings plc (IMCR)
NMS – Real vaqt narxi. Valyuta: USD
30.88
+0.34 (1.11%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
31.49
+0.61 (1.98%)
Bozordan keyin: Jun 26, 2026, 6:39 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
30.88
+0.34 (1.11%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
31.49
+0.61 (1.98%)
Bozordan keyin: Jun 26, 2026, 6:39 PM EDT
Immunocore Holdings plc, sho'ba korxonalari bilan birgalikda, Qo'shma Shtatlar, Yevropa va xalqaro miqyosda saraton, yuqumli kasalliklar va autoimmun kasalliklari bo'lgan bemorlar uchun immunomodulyatsion dorilarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya opere qilinmaydigan yoki metastatik uveal melanosomasini davolash uchun KIMMTRAKni taklif etadi. Shuningdek, u onkologiya dasturlarini ishlab chiqadi, jumladan, ilg'or terili melanosoma va adjuvant uveal melanosomasini davolash uchun 3-bosqich klinik sinovlarida bo'lgan tebentafusp; birinchi qator ilg'or terili melanosomani davolash uchun 3-bosqich klinik sinovlarida va turli xil o'smalar turlarini davolash uchun 1/2-bosqich klinik sinovlarida bo'lgan brenetafusp; kolorektal saraton kabi ilg'or qattiq o'smalarni davolash uchun 1/2-bosqich klinik sinovlarida bo'lgan IMC-R117C; va PRAMEni ifoda etuvchi o'smalari bo'lgan bemorlar uchun 1-bosqich klinik sinovlarida bo'lgan IMC-P115C. Bundan tashqari, kompaniya OIVni funksional davolash uchun 1-bosqich klinik sinovlarida bo'lgan IMC-M113V va gepatit B virusini funksional davolash uchun 1-bosqich klinik sinovlarida bo'lgan IMC-I109Vni ishlab chiqishda ishtirok etadi. Bundan tashqari, u 1-tip diabetni davolash uchun tadqiqotdan oldingi bosqichda bo'lgan IMC-S118AI va atopik dermatitni davolash uchun tadqiqotdan oldingi bosqichda bo'lgan IMC-U120AIni ishlab chiqadi. Kompaniya 1999 yilda tashkil etilgan va Buyuk Britaniyaning Abingdon shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bahija Jallal Ph.D. | CEO & Executive Director |
| Dr. Kripa Ram Ph.D. | Executive VP & Chief Operating Officer |
| Mr. John Goll III | SVP, Finance & Chief Accounting Officer |
| Mr. Sean D. Buckley | VP & Chief Information Officer |
| Mr. Sébastien Desprez | Vice President of Communications |
| Mr. Travis Alan Coy M.B.A. | CFO, Executive VP & Head of Corporate Development |
| Ms. Annelise Vuidepot Ph.D. | Senior VP, CTO and Research & UK Site Lead |
| Ms. Elizabeth Varki Jobes Esq., J.D. | Chief Compliance Officer |
| Ms. Lily Margaret Hepworth | Executive VP, General Counsel & Company Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-27 | 8-K | ef20075013_form8k.htm |
| 2026-05-08 | S-8 | ef20072226_s-8.htm |
| 2026-05-06 | 8-K | ef20072537_8k.htm |
| 2026-05-06 | 10-Q | imcr-20260331.htm |
| 2026-04-16 | DEF 14A | ny20070395x1_def14a.htm |
| 2026-04-16 | ARS | ny20070395x2_ars.pdf |
| 2026-02-25 | 8-K | ef20066378_8k.htm |
| 2026-02-25 | 10-K | imcr-20251231.htm |
| 2026-01-30 | 8-K | ef20064300_8k.htm |
| 2026-01-09 | 8-K | ef20062561_8k.htm |